NEW YORK – ERS Genomics, a vessel for intellectual property held by CRISPR pioneer Emmanuelle Charpentier, announced Tuesday a licensing deal with Applied StemCell.
Under the agreement, Milpitas, California-based Applied StemCell will commercialize CRISPR gene editing services and reagents.
"Applied StemCell has been a leading stem cell company … for many years," ERS Genomics CEO Eric Rhodes said in a statement. "It is exciting to see their expertise in cell and animal models being combined with the power of CRISPR gene editing."